

## Disclosures

Equity and consulting interests in, and royalty income from IP licensed to, Ocugenix, LLC  
 Advisory board position and equity in Opticent Health  
 Advisory board position and equity in IOP Medical Ltd.  
 Consulting interests in Annexon Inc.  
 Consulting interests in Pfizer  
 Consulting interests in Slack Inc./Vindico Medical Education  
 Consulting interests in Alcon Laboratories  
 Consulting interests in Aerie  
 Royalty income from Elsevier  
 Royalty income from the Massachusetts Eye and Ear Infirmary  
 Royalty income from IP licensed to Zeiss Optical  
 Rights in IP assigned to the University of Pittsburgh  
 Rights in IP assigned to New York University




---

---

---

---

---

---

---

---



## NOVEL APPLICATIONS OF LEADING-EDGE OCT IN THE DIAGNOSIS AND TREATMENT OF GLAUCOMA

JOEL S. SCHUMAN, MD

Professor of Ophthalmology, Neural Science, Neuroscience and Physiology and Biomedical, Electrical and Computer Engineering  
 Chairman, Department of Ophthalmology  
 Director, NYU Eye Center  
 NYU Langone Health  
 NYU School of Medicine  
 NYU Tandon School Of Engineering




---

---

---

---

---

---


---

---

### Advantages of going to visible


#### Higher Axial resolution

- Visible light OCT has an axial resolution ~1-1.4 microns in tissue (~2 um in eye)
- Near infrared OCT axial resolution ~ 5 microns



#### Retinal oximetry

- Visible light OCT accesses 10x higher hemoglobin absorption coefficients compared to near-infrared
- Oxygenated and deoxygenated hemoglobin have more distinct spectral features in visible compared to near-infrared



Pl et al. Biomedical Optics Express (2018)




---

---

---


---

---

---

---

---




---

---

---


---

---

---

---

---




---

---

---


---

---

---

---

---




---

---

---

---

---

---

---

---

## Retinal Oximetry with Visible Light OCT

- Blood Oxygen Saturation Rate ( $SO_2$ ):
 
$$\frac{c_{HbO_2}}{c_{Hb} + c_{HbO_2}}$$
- $SO_2$  as a biomarker to monitor retinal metabolism and provide a valuable early indicator of ocular disease
- A visible-light source is necessary for measuring  $sO_2$  with spectroscopic OCT
  - Absorption Coefficient of Hb is higher than that in the NIR spectral range, achieving more reliable intensity values for  $SO_2$  measurement
  - The shapes of the absorption spectra of Hb and HbO<sub>2</sub> are more distinctive.




Fig. 1. Logarithmic absorption extinction coefficients of oxygenated hemoglobin (HbO<sub>2</sub>) and deoxygenated hemoglobin (Hb) in the wavelength range from 400 nm to 1000 nm [16]. The much higher extinction coefficients in the visible range (vis-OCT) compared to the infrared range (standard OCT) provides a better contrast to quantify oxygen saturation (sO<sub>2</sub>).

[SHACHALIA,2018]




---

---

---

---

---

---

---

---


---

---

---

---

## Principle of retinal oximetry with vis-OCT



Nepper & Swethlow et al. Vision Research (2017)




---

---

---

---

---

---

---

---

---

---

---

---

## Scanning pattern

- Vis-OCT scans were obtained using two scanning modes:
  - For each eye of a healthy volunteer one pair of retinal major artery and vein in superior and inferior regions near the optic nerve head was scanned in raster mode with our prototype vis-OCT (8192 A-scans over 1 mm<sup>2</sup>, sampling interval = 0.12 μm).
  - Each eye of a healthy volunteer was scanned in circular mode with our prototype (12288 A-scans, circle size 3.37, #Bscans=16)




---

---

---

---

---

---

---

---

---

---

---

---

## Method

- Spectroscopic analysis was done on the raster or circular scans using short-time Fourier Transform (STFT).
- For reliable  $sO_2$  estimation, wavelength-dependent OCT amplitude from the same depth location across multiple A-lines were averaged.




---

---

---

---


---

---

---

---

## Oximetry




---

---

---


---

---

---

---

---




---

---

---


---

---

---

---

---




---

---

---

---

---


---

---

---

---

---




---

---

---

---

---


---

---

---

---

---




---

---

---

---

---

---

---

---

---

---

**AO-OCT images of GCL somas**

Zhoulin Liu et al., PNAS 2017; 114:4632-4637

PNAS

NYU Langone Health

---

---

---

---

---

---

---

---

## Conclusions

- Retinal oximetry is possible with vis-OCT
- Improved layer segmentation with vis-OCT
- Ganglion cells can be visualized with AO-OCT
  - Revolutionary opportunity to characterize cellular changes in glaucoma in the cells damaged by the disease
- Advances offer the potential to identify disease and progression or response to treatment by structural and other than structural means

NYU Langone Health

---

---

---

---

---

---

---

---

## Collaborations

|   |  |   |
|---|--|---|
| <u>IBM</u><br>Stefan Mauschke, PhD<br>Bhavna Antony, PhD<br>Rahil Garvani, PhD  | <u>MIT</u><br>James G. Fujimoto, PhD   | <u>Physical Sciences Inc</u><br>R. Daniel Ferguson, PhD<br><u>NYU Tandon</u><br>Guoqiang Gong, PhD<br>Ivan Seleznick, PhD |
| <u>Northwestern University</u><br>Hao Zhang, PhD<br><u>University of Pittsburgh</u><br>Ian A. Sigal, PhD<br>Matthew Smith, PhD<br>Ian Corner, MD, PhD<br>Nils Loewen, MD, PhD | <u>Georgia Tech</u><br>James Rahg, PhD<br><u>OHSU</u><br>David Huang, MD, PhD<br><u>Asan MC, U Ulsan</u><br>Kyung Rim Sung, MD | <u>US FDA</u><br>Daniel X. Hammer, PhD<br>Larry Kagemann, PhD<br><u>Tufts-NEMC</u><br>Jay S. Duker, MD                    |

NYU Langone Health

---

---

---

---

---

---

---

---

Advanced Ophthalmic Imaging Research Laboratory



Scott S. Schuman, MD  
Gabi Wollstein, MD  
Hiroshi Ishikawa, MD  
Zahava Kruse-Grisalesi, PhD  
Heather Livengood, PhD  
Alfonso Romeo, MD  
Zachary Steinberg  
Tanya Reich, BS  
Felix Livshits, MD, PhD, MBA  
Young-Seok Song, MD, PhD  
Mengting Liu, PhD  
Mengjie Wu, MS  
Katie Lucylonas, BS  
Sara Mack, BS  
Cecilia Salsedo, BS



NIH Grants: R01-EY025011, R01-EY013178, R01-EY023986, R01-EY029228, R01-EY011299, P30-EY008088, T32-EY017271  
Research to Prevent Blindness (New York, NY)



---

---

---

---

---

---

---

---



---

---

---

---

---

---

---

---